Mind Medicine (MindMed) Inc. (E:MMED*CA)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 1166 Alberni Steet, Suite 1604
Tel: N/A
Website: https://mindmed.co
IR: See website
Key People
Perry N. Dellelce
Chairman of the Board
Miriam Halperin Wernli
President, Director
Jamon Alexander Rahn
Chief Executive Officer, Director
David D. Guebert
Chief Financial Officer
Carol Nast
Chief Operating Officer
Bradford Cross
Chief Technology Officer
Donald Gehlert
Chief Scientific Officer
Robert Barrow
Chief Development Officer
Daniel R. Karlin
Chief Medical Officer
Business Overview
Mind Medicine (MindMed) Inc. is a Canada-based clinical-stage psychedelic medicine biotechnology company. The Company focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The Company's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.
Financial Overview
For the nine months ended 30 September 2021, MindMedicine (MindMed) Inc revenues was not reported. Net lossincreased from $21.4M to $74.3M. Higher net loss reflectsResearch and development increase of 78% to $17.5M(expense), Amortization increase from $413K to $7.7M(expense), General and administrative - remaining increasefrom $647K to $5.6M (expense).
Employees: 50 as of Dec 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $978.90M as of Sep 30, 2021
Annual revenue (TTM): $0.00M as of Sep 30, 2021
EBITDA (TTM): -$106.96M as of Sep 30, 2021
Net annual income (TTM): -$112.78M as of Sep 30, 2021
Free cash flow (TTM): -$50.75M as of Sep 30, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 420,745,804 as of Sep 30, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.